Abstract
Spironolactone and potassium canrenoate (aldosterone antagonist diuretics) are sometimes used in conjunction with digoxin for patient management. Spironolactone, potassium canrenoate, and their common metabolite canrenone interfere with serum digoxin measurement using various immunoassays. Recently a new enzyme‐linked chemiluminescent immunosorbent digoxin assay (ECLIA‐Digoxin) became commercially available for application on the ADVIA IMS 800i modular system (Bayer HealthCare, Tarrytown, NY). We investigated the potential interference of spironolactone and related compounds in this assay by comparing the results with the fluorescence polarization immunoassay (FPIA), which is known to have significant cross‐reactivity with these compounds as well as a turbidimetric assay for digoxin with no known cross‐reactivity with spironolactone and related compounds. Aliquots of drug free serum were supplemented with therapeutic and above therapeutic concentrations of spironolactone, canrenone, and potassium canrenoate, and apparent digoxin concentrations were measured. No apparent digoxin concentration was observed using the ECLIA‐Digoxin or turbidimetric assay. When serum pools prepared from patients receiving digoxin were further supplemented with these compounds, we observed no significant change in digoxin concentrations in the presence of these compounds with the ECLIA‐Digoxin. We conclude that this assay is virtually free from interferences from spironolactone, potassium canrenoate and their common metabolite canrenone. J. Clin. Lab. Anal. 20:204–208, 2006. © 2006 Wiley‐Liss, Inc.
Keywords: spironolactone, metabolite, interference, fluorescence polarization immunoassay, turbidimetric assay, enzyme‐linked immunosorbent assay
REFERENCES
- 1. Cook CS, Hauswald CL, Schoenhard GL, et al. Difference in metabolic profile of potassium canrenoate and spironolactone in rat: mutagenic metabolites unique to potassium canrenoate. Arch Toxicol 1988;61:201–212. [DOI] [PubMed] [Google Scholar]
- 2. Kojima K, Yamamoto K, Fujioka H, Kaneko H. Pharmacokinetics of spironolactone and potassium canrenoate in humans. J Pharmacobiodyn 1985;8:161–166. [DOI] [PubMed] [Google Scholar]
- 3. Vose CW, Boreham DR, Ford GC, Haskins NJ, Palmer RF. Identification of some human urinary metabolites of orally administered potassium canrenoate by stable isotope labeling techniques. Drug Metab Dispos 1979;7:226–232. [PubMed] [Google Scholar]
- 4. Morris RG, Frewin DB, Taylor WB, Glistak ML, Lehmann DR. The effect of renal and hepatic impairment and of spironolactone on serum digoxin assay. Eur J Clin Pharmacol 1988;34:233–239. [DOI] [PubMed] [Google Scholar]
- 5. Pleasants RA, Williams DM, Porter RS, Gadsden RH. Reassessment of cross‐reactivity of spironolactone metabolites with four digoxin assays. Ther Drug Monit 1989;11:200–204. [DOI] [PubMed] [Google Scholar]
- 6. Foukaridis GN. Influence of spironolactone and its metabolite canrenone on serum digoxin assays. Ther Drug Monit 1990;12;82–84. [DOI] [PubMed] [Google Scholar]
- 7. Stone JA, Soldin SJ. An update on digoxin. Clin Chem 1989;35:1326–1331. [PubMed] [Google Scholar]
- 8. Okazaki M, Tanigawara Y, Kita T, Komada F, Okumura K. Cross‐reactivity of TDX and OPUS immunoassay system for serum digoxin determination. Ther Drug Monit 1997;19:657–662. [DOI] [PubMed] [Google Scholar]
- 9. Steimer W, Muller C, Eber B, Emmanuilidis K. Intoxication due to negative canrenone interference in digoxin monitoring. Lancet [Letter] 1999;354:1176–1177. [DOI] [PubMed] [Google Scholar]
- 10. Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem 2002;48:507–516. [PubMed] [Google Scholar]
- 11. Steimer W. Lack of clinically significant interference by spironolactone with AxSYM Digoxin II assay only applies to low‐dose therapy with spironolactone [Letter]. Ther Drug Monit 2003;25:112–113. [DOI] [PubMed] [Google Scholar]
- 12. Datta P, Dasgupta A. A new turbidimetric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone. Ther Drug Monit 2003;25:478–482. [DOI] [PubMed] [Google Scholar]
- 13. Tal DM. 6,7‐dihydroxy‐6,7‐dihydrocanrenone isomers: improved synthesis and proton NMR study. Steroids 1989;54:113–122. [DOI] [PubMed] [Google Scholar]
- 14. Miller JJ, Valdes R. Methods for calculating cross reactivity in immunoassays. J Clin Immunoassay 1992;15:97–100. [Google Scholar]
- 15. Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady state serum levels of the sulfur containing metabolites. J Clin Pharmacol 1989;29:342–347. [DOI] [PubMed] [Google Scholar]
- 16. Karras K, Seifert W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate‐K in healthy man. Eur J Clin Pharmacol 1983;25:449–453. [DOI] [PubMed] [Google Scholar]
- 17. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate‐K in humans. J Pharmacol Exp Ther 1973;185:686–695. [PubMed] [Google Scholar]
- 18. Morris RG, Lagando PY, Lehmann DR, Frewin DB, Glistak ML, Burnet RB. Spironolactone as a source of interference in commercial digoxin immunoassays. Ther Drug Monit 1987;9:208–211. [DOI] [PubMed] [Google Scholar]
- 19. Dasgupta A, Kang E, Datta P. New enzyme‐linked immunosorbent digoxin assay on the ADVIA IMS 800i system is virtually free from interference of endogenous digoxin‐like immunoreactive factors. Ther Drug Monit 2005;27:139–143. [DOI] [PubMed] [Google Scholar]